Literature DB >> 10080486

Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing.

A M Atz1, I Adatia, J E Lock, D L Wessel.   

Abstract

OBJECTIVES: We compared the ability of inhaled nitric oxide (NO), oxygen (O2) and nitric oxide in oxygen (NO+O2) to identify reactive pulmonary vasculature in pulmonary hypertensive patients during acute vasodilator testing at cardiac catheterization.
BACKGROUND: In patients with pulmonary hypertension, decisions regarding suitability for corrective surgery, transplantation and assessment of long-term prognosis are based on results obtained during acute pulmonary vasodilator testing.
METHODS: In group 1, 46 patients had hemodynamic measurements in room air (RA), 100% O2, return to RA and NO (80 parts per million [ppm] in RA). In group 2, 25 additional patients were studied in RA, 100% O2 and 80 ppm NO in oxygen (NO+O2).
RESULTS: In group 1, O2 decreased pulmonary vascular resistance (PVR) (mean+/-SEM) from 17.2+/-2.1 U.m2 to 11.1+/-1.5 U.m2 (p < 0.05). Nitric oxide caused a comparable decrease from 17.8+/-2.2 U.m2 to 11.7+/-1.7 U.m2 (p < 0.05). In group 2, PVR decreased from 20.1+/-2.6 U.m2 to 14.3+/-1.9 U.m2 in O2 (p < 0.05) and further to 10.5+/-1.7 U.m2 in NO+O2 (p < 0.05). A response of 20% or more reduction in PVR was seen in 22/25 patients with NO+O2 compared with 16/25 in O2 alone (p = 0.01).
CONCLUSIONS: Inhaled NO and O2 produced a similar degree of selective pulmonary vasodilation. Our data suggest that combination testing with NO + O2 provides additional pulmonary vasodilation in patients with a reactive pulmonary vascular bed in a selective, safe and expeditious fashion during cardiac catheterization. The combination of NO+O2 identifies patients with significant pulmonary vasoreactivity who might not be recognized if O2 or NO were used separately.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080486     DOI: 10.1016/s0735-1097(98)00668-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  24 in total

Review 1.  Advances in pediatric pulmonary arterial hypertension.

Authors:  Dunbar Ivy
Journal:  Curr Opin Cardiol       Date:  2012-03       Impact factor: 2.161

Review 2.  Severe paediatric pulmonary hypertension: new management strategies.

Authors:  A Rashid; D Ivy
Journal:  Arch Dis Child       Date:  2005-01       Impact factor: 3.791

3.  Hyperoxia Reduces Oxygen Consumption in Children with Pulmonary Hypertension.

Authors:  Long Guo; Prashant Bobhate; Shine Kumar; Karunakar Vadlamudi; Tarek Kaddoura; Mohamed Elgendi; Paula Holinski; James Y Coe; Jennifer Rutledge; Ian Adatia
Journal:  Pediatr Cardiol       Date:  2017-03-18       Impact factor: 1.655

Review 4.  Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report.

Authors:  Darren B Taichman; Joe Ornelas; Lorinda Chung; James R Klinger; Sandra Lewis; Jess Mandel; Harold I Palevsky; Stuart Rich; Namita Sood; Erika B Rosenzweig; Terence K Trow; Rex Yung; C Gregory Elliott; David B Badesch
Journal:  Chest       Date:  2014-08       Impact factor: 9.410

Review 5.  Inhaled nitric oxide and related therapies.

Authors:  Frederick E Barr; Duncan Macrae
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

6.  Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response.

Authors:  B C Cannon; T F Feltes; J Kennard Fraley; R G Grifka; E M Riddle; J P Kovalchin
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

Review 7.  Pharmacotherapy for pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Clin North Am       Date:  2012-08-26       Impact factor: 3.278

Review 8.  Pulmonary Hypertension.

Authors:  Peter Oishi; Jeffrey R Fineman
Journal:  Pediatr Crit Care Med       Date:  2016-08       Impact factor: 3.624

Review 9.  Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.

Authors:  John S Kim; Julia McSweeney; Joanne Lee; Dunbar Ivy
Journal:  Pediatr Crit Care Med       Date:  2016-03       Impact factor: 3.624

10.  The role of nitric oxide synthase-derived reactive oxygen species in the altered relaxation of pulmonary arteries from lambs with increased pulmonary blood flow.

Authors:  Satyan Lakshminrusimha; Dean Wiseman; Stephen M Black; James A Russell; Sylvia F Gugino; Peter Oishi; Robin H Steinhorn; Jeffrey R Fineman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-05-18       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.